[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.5012/jkcs.2019.63.1.7

Crystal Form of Olmutinib

Lee, Chang-Yeob (College of Pharmacy, Duksung Women's University)
Sohn, Young-Taek (College of Pharmacy, Duksung Women's University)

Publication Information

Journal of the Korean Chemical Society / v.63, no.1, 2019 , pp. 7-11 More about this Journal

Abstract

Olmutinib, N-[3-({2-[4-(4-methylpiperazine-1-yl)aniline]thieno[3,2-d]Pyrimidin-4-yl}oxy)phenyl]prop-2-enamide dihydrochloride monohydrate, $Olita^{TM}$ is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that was developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd for the treatment of non-small cell lung cancer (NSCLC). The aim of this work was to investigate the existence of polymorphs and pseudopolymorphs of olmutinib. Three crystal forms of olmutinib have been isolated by recrystallization and characterized by differential scanning calorimetry (DSC), thermogravimetric (TG) analysis and powder X-ray diffractometry (PXRD). From the DSC and TG data it was confirmed that Form 1 is monohydrate, Form 2 is dihydrate, Form 3 is 1.5 hydrate. The PXRD patterns of three crystal forms were different respectively. After storage of 1 month at $2^{\circ}C$ , 24% RH (Relative Humidity), Form 1, Form 2, and Form 3 were not transformed.

Keywords

Olmutinib; Crystal form; DSC; TG; PXRD;

Citations & Related Records

Reference

1	Fiese, E. F.; Hagen, T. A. In The theory and practice of industrial pharmacy, Lachman, L., Lieberman, H. A., Kanig, J. L., Eds.; Lea & Febiger: Philadelphia, USA, 1986; p. 171.
2	Wells, J. In Pharmaceutics, Aulton, M. E., Ed.; Churchill Livingstone, Edinburgh, London, New York, Philadelphia, St.Louis, Sydney, Toronto, 2002; p. 113.
3	Rodriguez-Spong, B; Price, C. P; Jayasankar, A.; Matzger, A. J.; Rodriguez-Hornedo, N. Adv Drug Deliv Rev. 2004, 56, 241. DOI
4	Q6A International Conference on Harmonization; Guidance on Q6A Specifications, Federal Register 2000, 65, 83041.
5	Haleblian, J. J Pharm Sci. 1975, 64, 1269. DOI
6	Perlovich, G. L.; Blokhina, S. V.; Manin, N. G.; Volkova, T. V.; Tkachev, V. V. J. Therm. Anal. Calorim. 2013, 111, 655. DOI
7	Tak, S. R.; Sohn, Y. T. J. Therm. Anal. Calorim. 2016, 123, 2477. DOI
8	Dichi, E.; Legendre, B.; Sghaier, M. J. Therm. Anal. Calorim. 2014, 115, 1551. DOI
9	Griesser, U. J.; Weigand, D.; Rollinger, J. M.; Haddow, M.; Gstrein, E. J. Therm. Anal. Calorim. 2004, 77, 511. DOI
10	Maria, T. M. R.; Castro, R. A. E.; Silva, M. R.; Ramos, M. L.; Justino, L. L. G.; Burrows, H. D.; Canotilho, J.; Eusebio, M. E. S. J. Therm. Anal. Calorim. 2013, 111, 2171. DOI
11	Kuhnert-Brandstatter, M.; Burger, A. Pharm. Ind. 1972, 34, 187.
12	Liu, W.; Dang, L.; Wei, H. J. Therm. Anal. Calorim. 2013, 111, 1999. DOI
13	Szterner, P.; Legendre, B.; Sghaier, M. J. Therm. Anal. Calorim. 2010, 99, 325. DOI
14	Kim, E. S. Drugs 2016, 76, 1153. DOI
15	Brittain, H. G. In Polymorphism in Pharmaceutical Solids. Brittain, H. G., Ed.; Marcel Dekker: New York, Basel, 1999; p. 227.
16	Seo, H. O.; Sohn, Y. T. J. Therm. Anal. Calorim. 2015, 120, 749. DOI